Original Article

Allergic rhinitis is associated with poor asthma control in children with asthma

Eric P de Groot,1 Anke Nijkamp,1 Eric J Duiverman,2 Paul L P Brand1,3

ABSTRACT

Background Asthma and allergic rhinitis are the two most common chronic disorders in childhood and adolescence. To date, no study has examined the impact of comorbid allergic rhinitis on asthma control in children.

Objective To examine the prevalence of allergic rhinitis in children with asthma, and the impact of the disease and its treatment on asthma control.

Methods A cross-sectional survey in 203 children with asthma (5–18 years) using validated questionnaires on rhinitis symptoms (stuffy or runny nose outside a cold) and its treatment, and the paediatric Asthma Control Questionnaire (ACQ). Fraction of nitric oxide in exhaled air (FeNO) was measured with a Niox Mino analyser; total and specific IgE levels were assessed by the Immunocap system.

Results 157 children (76.2%) had symptoms of allergic rhinitis but only 88 of these (56.1%) had been diagnosed with the condition by a physician. ACQ scores were worse in children with allergic rhinitis than in those without the condition (p=0.012). An ACQ score ≥1.0 (incomplete asthma control) was significantly more likely in children with allergic rhinitis than in those without (OR 2.74, 95% CI 1.28 to 5.91, p=0.0081), also after adjustment for FeNO levels and total serum IgE. After adjustment for nasal corticosteroid therapy, allergic rhinitis was no longer associated with incomplete asthma control (OR 0.72, 95% CI 0.47 to 1.12, p=0.150).

Conclusion Allergic rhinitis is common in children with asthma, and has a major impact on asthma control. The authors hypothesise that recognition and treatment of this condition with nasal corticosteroids may improve asthma control in children, but randomised clinical trials are needed to test this hypothesis.

INTRODUCTION

Asthma and allergic rhinitis (AR) are the two most common chronic disorders in childhood and adolescence, and their prevalence rates have doubled over the past decades. Current prevalence rates of AR in countries with a Western lifestyle may be as high as 40%.1 It has long been recognised that AR and asthma commonly coexist, due to their similarities in anatomy, physiology and immunopathology.2 Surveys have shown that approximately 60–80% of children with asthma have symptoms of AR.3–7

In adults, it has been shown that AR has a major impact on asthma morbidity, and that treatment of AR helps to improve asthma control.8 Despite its high prevalence, there are surprisingly few studies on the effects of treatment of AR in children.9

METHODS

Study population

Between June 2008 and June 2009, consecutive patients aged 5–18 years visiting the Princess Amalia asthma clinic for a scheduled follow-up visit were approached for participation in this cross-sectional survey. Inclusion was continued over 1 year to allow all patients with asthma followed up at our clinic to participate in the survey.

Inclusion and exclusion criteria

Only patients fulfilling all of the following criteria were eligible for inclusion in the study: diagnosis of asthma, made by a paediatrician according to international standardised guidelines10, maintenance therapy with ICS for at least 3 months.

Key messages

What is the key question?

- The prevalence of allergic rhinitis in children with asthma, and the impact of the disease and its treatment on asthma control

What is the bottom line?

- Asthma and allergic rhinitis often coexist in children, and the presence of allergic rhinitis is associated with poorer asthma control

Why read on?

- This article analyses the relation of allergic rhinitis and asthma and the effect of allergic rhinitis therapy on asthma control.

Moreover, its impact on asthma in the paediatric age range has been poorly studied to date. A recent cross-sectional study in 404 French children with asthma showed symptoms of AR in 58% of the children, but no association with asthma severity was found.6 Conversely, a Japanese study of 150 children with asthma showed that exacerbations of upper and lower respiratory tract symptoms frequently coexisted, suggesting that AR does have an impact on asthma morbidity in children.3 To date, no study has examined the impact of comorbid AR on asthma control in children.

We designed this cross-sectional questionnaire based survey to determine the prevalence of AR in a Dutch population of children with asthma on inhaled corticosteroid (ICS) maintenance therapy, and the impact of AR on asthma control, level of lung function and exhaled nitric oxide.

Furthermore, it has been shown that AR helps to improve asthma control.8 Despite its high prevalence, there are surprisingly few studies on the effects of treatment of AR in children.
before the study; able to perform reproducible lung function testing; and proper understanding of Dutch language. Patients with serious bronchopulmonary, neuromuscular or cardiovascular comorbidity were excluded.

**Questionnaire**

Symptoms of AR and level of asthma control were assessed by applying two standardised and validated questionnaires. The International Study of Asthma and Allergies in Childhood (ISAAC) rhinitis questionnaire was used to assess the presence of symptoms of AR; asthma control was measured by the childhood Asthma Control Questionnaire (ACQ). Both questionnaires have been validated for the Dutch language and have been used in earlier studies in the Netherlands. Patients aged 12 years or older filled out the questionnaires themselves; in children younger than 12 years, the parents completed the questionnaires.

AR (ever) was defined as a positive answer to the question: ‘Has your child ever had a problem with sneezing, or a runny, or a blocked nose when he/she DID NOT have a cold or the flu?’ Aggregated ACQ scores <1.0 were considered to indicate well controlled asthma.16

**Pulmonary function and nitric oxide measurement**

Immediately after filling out the questionnaires, complete expiratory flow-volume loops were recorded according to European Respiratory Society guidelines on a Jaeger MasterScreen (Jaeger, Houston, Texas, USA) by experienced and certified pulmonary function assistants. The forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) were recorded, and expressed as a percentage of the predicted reference value. In addition, the fraction of nitric oxide in exhaled air (FeNO) was measured using the NIOX MINO device (Aerocrine, Solna, Sweden), according to standardised guidelines and expressed in parts per billion (ppb).

**Specific IgE to inhaled allergens**

Data on aeroallergen sensitisation were recorded from the chart if it had been obtained no longer than 2 years before the patient entered the study. The ImmunoCap system (Pharmacia Diagnostics, Uppsala, Sweden) was used for total and specific IgE assessments. As the detection limit of the assay was 0.35 kU/litre, sensitisation was defined as a specific IgE concentration ≥0.35 kU/litre. Screening tests were performed for the five major aeroallergens for children in the Netherlands (house dust mite, tree and grass pollen, cat and dog dander).

**Statistical analysis**

SPSS V.15.0 was used to analyse the data using t tests to compare means and χ2 tests to compare proportions. FeNO levels and ACQ scores were assessed by non-parametric methods because of their skewed distribution. Total IgE levels were log transformed before analysis. Multiple logistic regression analysis was performed to assess the relationship of dichotomised ACQ scores (well controlled vs incompletely controlled asthma, or ACQ < 1.0, indicating well controlled asthma, was 0.76 (0.33, IQR 0.04–0.67, 95% CI 1.28 to 5.91, p<0.0081). The distribution of ACQ scores in patients with and without AR is presented in figure 1. The median (IQR) ACQ in patients with AR was higher (0.67, IQR 0.17–1.33) than in those without AR (0.33, IQR 0.04–0.67, 95% CI for difference, p=0.024). This was more pronounced in children 5–12 years of age (median (IQR) in patients with AR 0.76 (0.17–1.33) and 0.53 (0–0.75) in those without, p=0.052) than in those 12–16 years of age (median (IQR) in patients with AR 0.76 (0.33–1.29), and in those without 0.50 (0.33–0.76), p=0.40).

**Results**

During the inclusion period, 206 patients fulfilling all inclusion criteria were approached for participation in the survey. None of these patients or their parents refused to participate. The clinical characteristics of the 206 patients are presented in table 1.

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Patient characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boys, number (%)</td>
<td>144 (69.9)</td>
</tr>
<tr>
<td>Age, mean (SD)</td>
<td>10.4 years (3.7)</td>
</tr>
<tr>
<td>BMI, mean (SD)</td>
<td>17.2 (3.1)</td>
</tr>
<tr>
<td>Asthma maintenance therapy, n (%)</td>
<td>195 (94.7)</td>
</tr>
<tr>
<td>ICS =250 µg/day*</td>
<td>143 (73.3%)</td>
</tr>
<tr>
<td>ICS 251—500 µg/day</td>
<td>44 (22.5%)</td>
</tr>
<tr>
<td>ICS &gt;500 µg/day</td>
<td>1 (&lt;1%)</td>
</tr>
<tr>
<td>Combination therapy (ICS + LABA)</td>
<td>51 (26.1%)</td>
</tr>
<tr>
<td>Allergic rhinitis therapy, n (%)</td>
<td>105 (51%)</td>
</tr>
<tr>
<td>Nasal corticosteroids</td>
<td>43 (40.9%)</td>
</tr>
<tr>
<td>Oral antihistamines</td>
<td>19 (18.1%)</td>
</tr>
<tr>
<td>Montelukast</td>
<td>4 (3.8%)</td>
</tr>
<tr>
<td>Combination</td>
<td>31 (29.5%)</td>
</tr>
<tr>
<td>FVC, mean (SD)</td>
<td>101.3% pred (12.0)</td>
</tr>
<tr>
<td>FEV1, mean (SD)</td>
<td>100.3% pred (14.7)</td>
</tr>
<tr>
<td>FeNO, median (IQR)</td>
<td>12.5 ppb (0–24)</td>
</tr>
<tr>
<td>IgE, median (IQR)</td>
<td>247 kU/litre (55–702)</td>
</tr>
</tbody>
</table>

*Daily dose of fluticasone (or equivalent). BML, body mass index (body weight (in kg) divided by height (in cm) squared); ICS, inhaled corticosteroids; LABA, long-acting β agonist; FeNO, fraction of nitric oxide in exhaled air; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; pred, predicted.

**Prevalence of allergic rhinitis**

A total of 157 patients (76.2%) had symptoms of AR, 144 of whom (91.7%) reported complaints during the last 12 months (current AR). AR was slightly more common in boys (112/144, 77.8%) than in girls (45/62, 72.6%), but the difference was not significant (p=0.40). A total of 88 patients (56.1% of patients with rhinitis symptoms) had received a doctor’s diagnosis of hay fever or AR. Symptoms of AR were considered to have an influence on daily activities in 102 children (64.9%): 72% of these reported mild limitation, 25% moderate and 3% severe limitation of daily activities.

**Impact on asthma control**

In three patients, some answers to the ACQ were missing; complete ACQ data were obtained in 203 patients. An aggregated ACQ score <1.0, indicating well controlled asthma, was 0.76 (0.33, IQR 0.04–0.67), and in those without AR (0.33, IQR 0.04–0.67, 95% CI 1.28 to 5.91, p<0.0081). The distribution of ACQ scores in patients with and without AR is presented in figure 1. The median (IQR) ACQ in patients with AR was higher (0.67, IQR 0.17–1.33) than in those without AR (0.33, IQR 0.04–0.67, 95% CI for difference, p=0.024). This was more pronounced in children 5–12 years of age (median (IQR) in patients with AR 0.76 (0.17–1.33) and 0.53 (0–0.75) in those without, p=0.052) than in those 12–16 years of age (median (IQR) in patients with AR 0.76 (0.33–1.29), and in those without 0.50 (0.33–0.76), p=0.40).

**Relationship to lung function and FeNO levels**

Most patients with asthma had normal levels of FEV1 and FVC (table 1), and there were no differences in mean FEV1 or FVC between those with and without AR (p=0.50 and 0.37, respectively).

FeNO, however, was significantly higher in patients with AR (median 15 ppb, IQR 0–28 ppb) than in those without (median 7 ppb, IQR 0–12, p=0.001) (figure 2). No significant differences in FeNO levels were found between patients treated with nasal
corticosteroids for AR and those who did not receive this treatment ($p = 0.816$).

**IgE levels and aeroallergen sensitisation**

Data on total serum IgE levels and aeroallergen sensitisation obtained no more than 2 years before the survey were available in 130 patients (63.1%). Total IgE levels were higher in patients with AR (geometric mean 680 kU/litre) than in those without (geometric mean 323 kU/litre, 95% CI of difference 102 to 612, $p = 0.020$) (figure 3). The proportion of patients with aeroallergen sensitisation was comparable in those with (97.2%) and those without AR (91.7%, $p = 0.20$); only grass pollen sensitisation differed between these groups (table 2). Patients with AR had a higher median number of aeroallergens to which they were sensitised (median 3, IQR 2–5) than children without AR (median 2, IQR 1–3, $p = 0.33$).

**Relationship of ACQ scores to allergic rhinitis, adjusted for degree of inflammation or sensitisation**

To establish whether the relationship of AR to ACQ scores was confounded by the degree of lower airway inflammation, or by the severity of allergen sensitisation, we built multiple logistic regression models with ACQ (dichotomised in scores $<1.0$ (well controlled asthma) or $\geq 1.0$ (incompletely controlled asthma)) as the dependent variable. In these models, the significant association of AR to low ACQ scores remained significant after adjustment for FeNO levels (OR 2.78, 95% CI 1.02 to 7.40, $p = 0.028$) or the number of aeroallergen sensitisations (OR 2.78, 95% CI 1.02 to 7.40, $p = 0.028$).

We also examined whether treatment for AR influenced the association of AR to ACQ scores. The results are presented in table 3. Reported use of rhinitis medication in general did not remove the significant impact of AR on ACQ scores ($p = 0.55$). However, patients who used nasal corticosteroids for AR, either alone or in combination with antihistamines or montelukast, had lower ACQ scores (median 0.58, IQR 0.17–1.17) than those with AR who did not use nasal corticosteroids (median 1.0, IQR 0.67–1.83), although the difference did not reach statistical significance ($p = 0.154$). After adjusting for use of nasal corticosteroids in a multiple logistic regression model, the relationship of AR to ACQ scores was no longer significant (OR 0.72, 95% CI 0.47 to 1.12, $p = 0.150$, table 3). In the 157 patients with AR symptoms, however, nasal corticosteroid therapy was not associated with ACQ scores $<1.0$ in a logistic regression model after adjustment for age and gender (OR 1.16, 95% CI 0.60 to 2.17, $p = 0.664$).
was not significant in patients who received nasal corticosteroid treatment for AR but remained significant in those not treated for rhinitis symptoms, or those receiving only oral antihistamines or montelukast. This suggests that recognition of AR in patients with asthma, and its prompt treatment with nasal corticosteroids, may improve asthma control in paediatric patients. Randomised clinical trials are required to test this hypothesis.

The rhinitis prevalence of 76% in this study is comparable to previous studies on AR in children with asthma.3–7 Despite this high prevalence, surprisingly few studies have examined the impact of AR on asthma morbidity in children,20,21 and the few results available to date have been contradictory.5,6 Our study is novel in that the main focus of our analysis was the impact of AR on asthma control and daily life activity. Although the complaints had an influence on daily life in almost two-thirds of patients (64.9%), almost half (43.9%) of patients with AR had not been diagnosed or treated as such by a physician. This may be caused either by underreporting by patients (or their parents) or poor recognition of rhinitis symptoms by doctors. Although the symptoms of AR (runny or stuffed nose without having a cold) may be confused with a cold or flu-like symptoms, the duration of such symptoms (>14 days) should prompt the physician to diagnose AR.3 The influence of AR on daily activities in our study was comparable to that reported by others.21

In a large survey in the USA, parents of children with AR were more likely to describe physical, mental and emotional, and social problems in their children.22

The main finding of our study was that AR had a significant influence on the degree of asthma control, even when asthma was well controlled in the large majority (65%) of patients participating in our survey. ACQ scores were higher in patients with AR than in those without (figure 1), and ACQ scores ≥1.0 (indicating incompletely controlled asthma)16 were more likely in this group of patients (table 3). Although aeroallergen sensitisation tended to be more common in patients with AR than in those without (table 2), the relationship between the presence of AR and incomplete asthma control remained significant after adjustment for total serum IgE levels or the number of aeroallergens to which the patient was sensitised. We have previously shown that sensitisation to numerous allergens is associated with a more severe clinical atopic phenotype.23 Apparently, the relationship of AR to asthma control is independent of this phenomenon of polysensitization.

The significant influence of AR on asthma control suggests that treatment of AR may help to improve asthma morbidity. In a retrospective cohort study in 4944 adult patients, those who were treated for AR had a significantly lower risk (6.6% vs 1.3%, p=0.001) of subsequent asthma-related events such as emergency department visits or hospitalisation than those who were not treated for AR.24 Two recent randomised controlled trials in

### Table 2

<table>
<thead>
<tr>
<th>Aleroylaarkennatega (n=131)</th>
<th>Aleroylaarkennatega (n=27)</th>
<th>p Autent</th>
</tr>
</thead>
<tbody>
<tr>
<td>House dust mite</td>
<td>86 (82.7)</td>
<td>21 (77.8)</td>
</tr>
<tr>
<td>Cat dander</td>
<td>58 (51.3)</td>
<td>8 (30.8)</td>
</tr>
<tr>
<td>Dog dander</td>
<td>64 (56.1)</td>
<td>11 (40.7)</td>
</tr>
<tr>
<td>Grass pollen</td>
<td>62 (61.4)</td>
<td>7 (26.9)</td>
</tr>
<tr>
<td>Tree pollen</td>
<td>45 (50.6)</td>
<td>5 (26.3)</td>
</tr>
<tr>
<td>Any aeroallergen</td>
<td>105 (97.2)</td>
<td>22 (91.7)</td>
</tr>
</tbody>
</table>

### Table 3

<table>
<thead>
<tr>
<th>Association of allergic rhinitis to Asthma Control Questionnaire (ACQ) score &lt; or ≥1.0 (indicating well or incompletely controlled asthma, respectively), adjusted for treatment for allergic rhinitis, in 203 patients with asthma with allergic rhinitis symptoms</th>
<th>OR* (95% CI)</th>
<th>p Autent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unadjusted</td>
<td>2.74 (1.28 to 5.91)</td>
<td>0.0081</td>
</tr>
<tr>
<td>Adjusted for any treatment for allergic rhinitis</td>
<td>2.41 (1.08 to 5.39)</td>
<td>0.033</td>
</tr>
<tr>
<td>Adjusted for use of oral antihistamines</td>
<td>2.62 (1.22 to 5.67)</td>
<td>0.014</td>
</tr>
<tr>
<td>Adjusted for use of nasal corticosteroids</td>
<td>0.72 (0.47 to 1.12)</td>
<td>0.150</td>
</tr>
</tbody>
</table>

*OR for ACQ ≥1.0 (incompletely controlled asthma) in patients with allergic rhinitis compared with those without allergic rhinitis.

---

**DISCUSSION**

This study shows that AR is a common and relevant comorbid condition in patients with asthma. The large majority (76%) of patients with asthma in our study had symptoms of AR, and the presence of AR had a significant influence on asthma control, independent of lower airway inflammation or aeroallergen sensitisation. The association of AR to level of asthma control

---

**Figure 3** Total serum IgE levels in patients with asthma with and without allergic rhinitis. Horizontal bars represent median values. IgE levels are significantly higher in patients with asthma and allergic rhinitis than in those without allergic rhinitis (p=0.020).
Asthma

adults examined the effect of intranasal steroids on asthma. In one study, although nasal corticosteroid therapy improved nasal inspiratory flow and rhinitis quality of life, there was no inhaled steroid sparing effect of treating AR with nasal corticosteroids.25 In the other study, treatment of AR with nasal steroids was associated with a non-significant trend in improving asthma control test scores (p=0.08).25 26 No such randomised trials have been performed in children. One study showed that administration of an ICS through a valved holding chamber with face-mask improved nasal symptoms but had no influence on asthma symptoms or lung function in children with asthma and AR.27 Asthma control was not assessed in this study. Our results suggest that nasal corticosteroid treatment of AR, but not therapy with antihistamines or montelukast, may improve asthma control in children. The significant relationship of AR symptoms to incomplete asthma control disappeared after adjusting for nasal corticosteroid therapy (table 3), although there was no direct relationship between nasal corticosteroid therapy and ACG score when only the patients with AR were analysed. This may be due to loss of statistical power to detect such a relationship in the smaller subset of patients with AR symptoms. This observation is in line with previous studies showing the superiority of nasal corticosteroids over other treatment modalities in children with AR.9 In our study, AR had no impact on pulmonary function in patients with asthma. The overall normal level of lung function in our study group (table 1) is in accordance with a previous report from our clinic.28 However, studies in adults have demonstrated a modest improvement in FEV1 (mean 5.45%, 95% CI 1.95% to 8.96%, p=0.004) in patients with asthma after treatment for AR.28 Such an effect on pulmonary function is unlikely to be found in children because the room for improvement is too small. Therefore, studies on AR treatment in children with asthma should focus on asthma control and exacerbations as primary endpoints. Although FeNO was higher in patients with AR than in those without (figure 2), the relationship between AR and poor asthma control remained significant after adjustment for FeNO levels, and nasal corticosteroid treatment was associated with lower FeNO levels. Previous studies have shown that a subgroup of children with asthma have persistently high FeNO levels, even when treated with high-dose ICS therapy.29 30 Our observations indicate that treatment with nasal corticosteroids does not alter this. As a result, FeNO is probably not a useful endpoint in studies of nasal corticosteroid effects in children with asthma and AR. The cause of the higher FeNO levels in patients with AR is not entirely clear. Although it is conceivable that allergic inflammation of nasal mucosa could increase local nitric oxide production, and that this may increase nasal contribution to FeNO measurements, the measurement technique for FeNO is intended to avoid nasal contamination.23 Therefore, this is unlikely to be the main reason for the higher FeNO levels observed in our patients with AR. Two alternative explanations should be considered. First, it may be argued that patients with asthma and AR have a more severe atopic phenotype.30 31 and this is reflected by higher FeNO levels. Second, because there is cross-talk between nasal and lower airway mucosa,32 33 ongoing nasal inflammation may increase eosinophilic lower airway inflammation and increase FeNO levels.

The main limitation of our study is its cross-sectional nature. Associations found in cross-sectional studies should be interpreted cautiously. Although the results of our study strongly suggest that AR has a significant negative impact on asthma morbidity in children, and that nasal corticosteroid treatment may eliminate this, prospective, preferably randomised controlled studies are needed to confirm this. Second, it may be argued that our definition of AR was non-specific, including all children with rhinitis symptoms outside a cold. Although this definition indeed comprises (IgE-mediated) AR and other causes of chronic rhinitis, AR is usually defined in the same way as in our study, in clinical practice and in research.34 35 Finally, we would like to add a cautionary note in generalising our results. Our study was performed in a hospital-based paediatric asthma clinic, in which patients are only seen and followed up when referred by a general practitioner, most commonly because of difficult to control asthma. That this may introduce selection bias is perhaps illustrated by the high prevalence of allergic sensitisation in our cohort (table 2). Further studies are needed to examine the effect of AR and its treatment on asthma control in children in other settings.

In summary, asthma and AR often coexist in children, and the presence of AR is associated with poorer asthma control, independent of FeNO and allergen sensitisation levels. Despite its impact on daily life activities on asthma control, AR is frequently unrecognised and undertreated. Recognition of AR in children with asthma and adequate treatment with nasal corticosteroids are likely to improve asthma control. This is particularly relevant in children with difficult-to-treat asthma. Randomised controlled trials on the effects of AR treatment on asthma control in children with asthma and AR are urgently needed.

Competing interests None.

Ethics approval Medical Ethics Committee Isala klinieken Zwolle.

Contributors Eric de Groot is the primary author. Research is conducted by Eric de Groot and Ankie Nijkamp. Eric Duiverman and Paul Brand have contributed by extensive editing and advising on the paper.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES
Allergic rhinitis is associated with poor asthma control in children with asthma

Eric P de Groot, Anke Nijkamp, Eric J Duiverman and Paul L P Brand

Thorax 2012 67: 582-587 originally published online January 2, 2012
doi: 10.1136/thoraxjnl-2011-201168

Updated information and services can be found at:
http://thorax.bmj.com/content/67/7/582

These include:

References
This article cites 34 articles, 6 of which you can access for free at:
http://thorax.bmj.com/content/67/7/582#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Asthma (1782)
Child health (843)
Ear, nose and throat/otolaryngology (218)
TB and other respiratory infections (1273)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/